531633 logo

Lincoln Pharmaceuticals Limited Stock Price

BSE:531633 Community·₹10.6b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

531633 Share Price Performance

₹529.20
-143.85 (-21.37%)
₹529.20
-143.85 (-21.37%)
Price ₹529.20

531633 Community Narratives

There are no narratives available yet.

Recent 531633 News & Updates

Lincoln Pharmaceuticals Limited Key Details

₹6.3b

Revenue

₹2.9b

Cost of Revenue

₹3.4b

Gross Profit

₹2.5b

Other Expenses

₹863.5m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
43.11
Gross Margin
53.90%
Net Profit Margin
13.71%
Debt/Equity Ratio
0%

Lincoln Pharmaceuticals Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet established dividend payer.

0 Risks
2 Rewards

About 531633

Founded
1979
Employees
1853
CEO
Mahendrabhai Patel
WebsiteView website
www.lincolnpharma.com

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia. Lincoln Pharmaceuticals Limited was incorporated in 1979 and is based in Ahmedabad, India.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Indian Market Performance

  • 7 Days: 1.8%
  • 3 Months: -1.3%
  • 1 Year: -2.3%
  • Year to Date: 1.1%
Over the last 7 days, the market has risen 1.8%, driven by gains of 2.6% in the Financials sector. As for last year, the market performance has been flat. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›